###begin article-title 0
Tumor Necrosis Factor Receptor Superfamily, Member 1B Haplotypes Increase or Decrease the Risk of Inflammatory Bowel Diseases in a New Zealand Caucasian Population
###end article-title 0
###begin p 1
Recommended by Robert Wyllie
###end p 1
###begin p 2
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 2
###begin p 3
###xml 1134 1137 1134 1135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#967;</italic>
###xml 1137 1138 1135 1136 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1155 1156 1153 1154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1193 1196 1191 1192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#967;</italic>
###xml 1196 1197 1192 1193 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1214 1215 1210 1211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 529 537 <span type="species:ncbi:9606">patients</span>
###xml 1103 1111 <span type="species:ncbi:9606">patients</span>
###xml 1423 1431 <span type="species:ncbi:9606">patients</span>
Inflammatory bowel diseases (IBDs) comprising Crohn disease (CD) and ulcerative colitis (UC) are chronic inflammatory conditions with polygenic susceptibility. Interactions between TNF-alpha and TNF-alpha receptor play a fundamental role in inflammatory response. This study investigates the role that selected single nucleotide polymorphisms (SNPs) and haplotypes in the TNF-alpha receptor (TNSFRSF1B) gene play in the risk of IBD in a New Zealand Caucasian population. DNA samples from 388 CD, 405 UC, 27 indeterminate colitis patients, and 293 randomly selected controls, from Canterbury, New Zealand were screened for 3 common SNPs in TNSFRSF1B: rs1061622 (c.676T > C), rs1061624 (c.*1663A > G), and rs3397 (c.*1690T > C), using TaqMan technologies. Carrying the rs1061624 variant decreased the risk of UC in the left colon (OR 0.73, 95% CI = 0.54-1.00) and of being a smoker at diagnosis (OR 0.62; 95% CI = 0.40-0.96). Carrying the rs3397 variant decreased the risk of penetrating CD (OR 0.62, 95% CI = 0.40-0.95). Three marker haplotype analyses revealed highly significant differences between CD patients and control subjects (chi2 = 29.9, df = 7, P = .0001) and UC cases and controls (chi2 = 46.3, df = 7, P < .0001). We conclude that carrying a 3-marker haplotype in the TNSFRSF1B gene may increase (e.g., haplotype of GGC was 2.9-fold more in the CD or UCpatients) or decrease (e.g., TGT was 0.47-fold less in UC patients) the risk of IBD in a New Zealand Caucasian population.
###end p 3
###begin title 4
1. Introduction
###end title 4
###begin p 5
###xml 286 287 286 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 476 477 476 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 644 645 644 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 761 762 761 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 868 869 868 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 557 565 <span type="species:ncbi:9606">children</span>
Inflammatory bowel diseases (IBDs), including Crohn disease (CD) and ulcerative colitis (UC), provide a good example of a disorder for which there is compelling evidence for genetically determined susceptibility that interacts with environmental factors, including microbiota and diet [1]. It is clear that there are strong ethnic differences in IBD susceptibility, and that different populations may have varying levels of genetic involvement, with distinctive risk alleles [2]. For example, although there is a very low incidence of CD in Bangladesh, the children of Bangladesh immigrants to the UK show a very high incidence of the disease [2]. As recently as 2005, it seemed that a maximum of 10-12 genetic loci could be involved in disease susceptibility [3], but whole genome association studies have changed the landscape such that a more recent meta-analysis [4] suggested involvement of more than 30 different loci. It becomes important to establish which loci are relevant to individual population groups living in specific locations.
###end p 5
###begin p 6
###xml 181 182 181 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 509 510 509 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 511 513 511 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 758 760 758 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
The prevalence and incidence of IBD in New Zealand are believed to have increased substantially in recent years, although stringently collated data are not available prior to 2004 [5]. As at 1 June 2005, Gearry et al. (2006) reported a prevalence of IBD in Canterbury, New Zealand, as 308.3 per 100 000 subjects (155.2 with CD and 145 with UC per 100 000). Although we have previously associated polymorphisms in several genes including NOD1&2, TLR4, DLG5, ATG16L1, and IL23R with risk of IBD in New Zealand [6-12], these only increase the IBD risk to a small extent and cannot explain the high New Zealand disease incidence. For example, carrying the common NOD2 1007-femtdsecond mutation increased the risk of CD 4.4 fold (95% confidence interval 1.6-12) [12].
###end p 6
###begin p 7
###xml 33 38 33 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 117 118 113 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 141 146 137 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 248 253 240 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 337 338 325 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 340 342 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 358 363 346 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 720 722 704 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 780 785 764 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 839 844 819 820 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 940 942 916 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 1006 1008 982 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 1009 1011 985 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 1093 1095 1069 1071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
Tumor necrosis factor-alpha (TNF-alpha) is a proinflammatory cytokine that plays a central role in IBD pathogenesis [8]. An inhibitor of TNF-alpha, infliximab (IFB), is an effective treatment of moderate to severe IBD, and polymorphisms in the TNF-alpha gene not only affect the phenotype of IBD, but may also impact IFB susceptibility [8, 13]. However, TNF-alpha does not work independently in the cell, but acts through binding to two receptors, TNF receptor superfamily, member 1A (TNFRSF1A or p55/p60) and TNF receptor superfamily, member 1B (TNFRSF1B, also called TNFR, p75/p80). TNFRSF1B is the larger of these receptors, being present on many cell types, and strongly expressed on stimulated T and B lymphocytes [14]. There is evidence that it regulates the binding of TNF-alpha to TNFRSF1A, and thus may regulate the levels of TNF-alpha necessary to stimulate the action of the transcription factor, nuclear factor-kappa B (NF-kB) [15]. The gene for TNFRSF1B is located on chromosome 1p36.3-p36.2 [16-18], which coincides with the previously identified IBD susceptibility locus, IBD7 [19].
###end p 7
###begin p 8
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 262 269 262 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab1">Table 1</xref>
###xml 402 403 402 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 484 486 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 488 490 488 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
Single nucleotide polymorphisms (SNPs) in TNFRSF1B have been suggested to modulate the risk of a number of autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, and CD [20-24]. This study considers the role of three SNPs in TNFRSF1B Table 1 on the overall risk or phenotype of IBD in a New Zealand Caucasian population, recruited from the Canterbury region in New Zealand [5] 2006. These SNPs were previously associated with CD risk in other populations [22, 23].
###end p 8
###begin title 9
2. Materials and Methods
###end title 9
###begin title 10
###xml 11 23 <span type="species:ncbi:9606">Participants</span>
2.1. Study Participants
###end title 10
###begin p 11
###xml 174 175 174 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 360 362 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 522 524 522 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 61 73 <span type="species:ncbi:9606">participants</span>
The cases in this study are a random subset of the Caucasian participants of the Canterbury Inflammatory Bowel Disease Project, which has been described in detail elsewhere [5]. All subjects consented to collection of peripheral blood for DNA extraction and genotyping. Phenotypic characteristics of this cohort are described in more detail by Tarrant et al. [25]. The database included their clinical diagnosis and IBD phenotype as defined using standard diagnostic criteria and using the Montreal Classification system [26]. The Montreal classification was current as of 1 June 2005.
###end p 11
###begin p 12
###xml 136 143 136 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab2">Table 2</xref>
###xml 7 19 <span type="species:ncbi:9606">participants</span>
###xml 28 40 <span type="species:ncbi:9606">participants</span>
###xml 76 88 <span type="species:ncbi:9606">participants</span>
###xml 149 161 <span type="species:ncbi:9606">participants</span>
###xml 199 207 <span type="species:ncbi:9606">patients</span>
388 CD participants, 403 UC participants, and 27 indeterminate colitis (IC) participants were genotyped for this study, as described in Table 2. All participants self-reported European ancestry, and patients who self-reported having any Maori or other non-Caucasian ancestry are not included.
###end p 12
###begin p 13
###xml 36 37 36 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 182 184 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
The New Zealand Caucasian controls (n = 293) were selected at random from the electoral roll, comprising 93% of the population over eighteen years of age in Canterbury, New Zealand [27]. 
###end p 13
###begin title 14
2.2. Applied Biosystems TaqMan SNP Genotyping Assay
###end title 14
###begin p 15
###xml 185 192 185 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab3">Table 3</xref>
###xml 336 337 336 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x</italic>
###xml 369 370 369 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x</italic>
SNPs were genotyped using the TaqMan MGB diallelic discrimination system. Probes and oligonucleotides were obtained from Applied Biosystems using the Assay-by-Design product (listed in Table 3). For the marker c.676T > C (rs1061622) a predesigned SNP genotyping assay was available (C_8861232_20). The reactions were prepared by using 2x TaqMan Universal Master Mix, 40x SNP Genotyping Assay Mix, DNase-free water, 10 ng genomic DNA in a final volume of 5 uL per reaction. The PCR amplification was performed using the ABI Prism 7900 HT sequence-detector machine under the following conditions: 10 minutes 95degreesC enzyme activation followed by 40 cycles at 92degreesC for 15 seconds and 60degreesC for 1 minute (annealing/extension). The allelic discrimination results were determined after the amplification by performing an endpoint read. To estimate genotype accuracy approximately 5% of the samples, that is, 70 cases were genotyped in duplicate or triplicate for each of the markers. No conflicted duplicate genotypes were detected.
###end p 15
###begin title 16
2.2.1. Statistical Analysis
###end title 16
###begin p 17
###xml 24 26 24 26 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 624 635 624 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">haplo.stats</italic>
###xml 642 644 642 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31b">28</xref>
###xml 855 862 855 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab2">Table 2</xref>
###xml 793 800 <span type="species:ncbi:9606">patient</span>
The allelic trend test [26] and Fisher's exact genotypic test were used to compare case and control allele frequencies. An exact test was used to test for departures from Hardy-Weinberg equilibrium (HWE) in the case and the control samples [27]. Allelic odds ratios were calculated and confidence intervals for the allelic odds ratio were also calculated under the assumption of HWE in the cases and the control groups. Logistic regression analysis was used to examine the relationship between genotypes and disease of CD, UC, and IBD using SAS (V9.1 SAS Institute., Cary, NC, USA). Haplotype analysis was carried out using haplo.stats in R [28] to test associations between haplotypes and traits. We also performed an exploratory analysis of allele frequency differences between controls and patient subgroups using the clinical characteristics given in Table 2.
###end p 17
###begin title 18
3. Results
###end title 18
###begin p 19
###xml 249 257 249 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab4">Tables 4</xref>
###xml 262 263 262 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab5">5</xref>
###xml 204 212 <span type="species:ncbi:9606">patients</span>
###xml 402 410 <span type="species:ncbi:9606">patients</span>
No significant deviation from Hardy-Weinberg Equilibrium was found in the control group for all three SNPs. For each of the polymorphisms studied, the risks of carrying the variant was compared CD and UC patients with the control group, as shown in Tables 4 and 5. There was no significant difference in the allele frequencies of the TNFRSF1B rs1061622, rs1061624, and rs3397 variants between CD or UC patients and healthy control subjects.
###end p 19
###begin p 20
###xml 455 463 <span type="species:ncbi:9606">patients</span>
Individuals carrying the rs1061622 variant showed no significant differences from those carrying the reference allele (the G allele), for overall risk of IBD or for any phenotypic class. No significant differences found any of the age at first diagnosis, any location of CD and UC, or CD behavior. Having any relatives with IBD, bowel resection, smoke at diagnosis, ever used immunomodulators, or any EIMs were not significanty different between CD or UC patients and controls.
###end p 20
###begin p 21
###xml 170 171 170 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 305 306 305 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 237 245 <span type="species:ncbi:9606">patients</span>
For the rs1061624 variant, those individuals carrying the A allele had a decreased probability of developing UC located in the left colon (OR = 0.73, 95% CI = 0.54-1.00, P = .05). Carrying the A allele also reduced the probability of UC patients having smoked at diagnosis (OR = 0.62, 95% CI = 0.40-0.96, P = .03) but showed no statistically significant effects in patterns of CD disease risk.
###end p 21
###begin p 22
###xml 249 250 249 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 477 484 477 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab4">Table 4</xref>
###xml 348 356 <span type="species:ncbi:9606">patients</span>
Those individuals carrying the variant TNFRSF1B rs3397 C allele showed a statistically significant reduction in the probability of developing CD with penetrating behavior, as compared with those carrying the T allele (OR = 0.62, 95% CI = 0.40-0.95, P = .03). No other phenotypes showed significant effects in patterns of disease risk of CD. For UC patients, those individuals carrying the variant rs3397 C allele showed no statistically significant effects in patterns of IBD (Table 4).
###end p 22
###begin title 23
3.1. Haplotype Analysis
###end title 23
###begin p 24
###xml 0 7 0 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab6">Table 6</xref>
###xml 330 331 330 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 524 525 524 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 239 247 <span type="species:ncbi:9606">patients</span>
Table 6 summarizes the results of haplotype analysis of the three TNFRSF1B SNPs (rs1061622, rs1061624, and rs3397). Haplotype frequencies were estimated, and association analyses were performed with respect to CD and UC in New Zealand IBD patients and Caucasian controls. A score for each haplotype (Hap-score) was calculated and P-value also calculated for the significance of each Hap-score. A positive hap-score implies that the haplotype occurs more frequently in the CD or UC case group than control subjects. A global P-value tests the overall association between haplotypes and the response.
###end p 24
###begin p 25
###xml 98 101 98 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#967;</italic>
###xml 101 102 99 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 119 120 117 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 274 275 272 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 312 313 310 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 456 457 454 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 494 495 492 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 833 834 831 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 939 940 937 938 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 67 75 <span type="species:ncbi:9606">patients</span>
###xml 908 916 <span type="species:ncbi:9606">patients</span>
There was a significant difference between these haplotypes for CD patients and control subjects (chi2 = 29.9, df = 7, P = .0001). In the three SNPs (rs1061622, rs1061624, and rs3397) in CD, the frequencies of haplotypes of GGC (9.1% for case versus 3.1% for control group, P = .005) and TAT (17.2% versus 6.4%, P = .001) were significantly different, with haplotypes GGC and TAT occurring more in CD cases than the control group. TAC (21.0% versus 27.7%, P = .06) and TGT (14.5% versus 23.6%, P = .06) were marginally significantly different between case and control groups, occurring less frequently in the cases. Haplotype TAC was the most common, with Hap-frequencies of 24.1%. Haplotype GGT was the most uncommon in CD case (3.9%) and control (3.3%) subjects, but occurred at equal frequencies in both (Hap-frequencies of 3.6%, P > .05). Haplotypes GAC, GAT, and TGC occurred at equal frequencies in CD patients and control subjects (P > .05).
###end p 25
###begin p 26
###xml 114 117 114 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#967;</italic>
###xml 117 118 115 116 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 135 136 133 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 271 272 269 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 308 309 306 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 343 344 341 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 383 384 381 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 529 530 527 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 692 693 690 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 590 598 <span type="species:ncbi:9606">patients</span>
###xml 782 790 <span type="species:ncbi:9606">patients</span>
There were also significant associations between these haplotypes for UC cases as compared with control subjects (chi2 = 46.3, df = 7, P < .0001). For the three marker haplotypes (rs1061622, rs1061624, and rs3397), the frequencies of haplotypes of GGC (9.1% versus 3.1%, P < .0001), TAC (17.9% versus 27.7%, P = .005), TAT (17.0% versus 6.4%, P = .006), and TGT (11.2% versus 23.6%, P = .0007) were significantly different between case and control subjects. Haplotype TAC was the most common in UC cases (Hap-frequency of 27.8%, P = .005), whereas haplotype GGT was the most uncommon in UC patients and control subjects, with frequencies of 3.6% and 3.3%, respectively (Hap-frequency = 3.4%, P = .53). The frequencies of GAC and TGC were lower and the frequency of GAT higher in UC patients than control subjects, but there was no statistically significant difference between them.
###end p 26
###begin title 27
4. Discussion
###end title 27
###begin p 28
The present results show that carrying a single variant allele in TNFRSF1B c.676T > C, 1663A > G, or 1690T > C has no significant effect on the overall risk of either CD or UC. However, the risk of certain phenotypes is affected by either of the latter two variant alleles. More striking, however, is the effect of carrying certain haplotypes, and specific combinations may either increase or decrease the risk of either CD or UC in the New Zealand Caucasian population, with strong statistical significance.
###end p 28
###begin p 29
###xml 64 66 64 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">29</xref>
###xml 905 906 905 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
TNFRSF1B is the main TNF receptor found on circulating T cells [14]. The gene contains 10 exons, spanning around 26 kb of genomic DNA and encoding 415 amino acids [14]. Cysteine-rich extracellular regions, comprising three to six disulfide-linked domains, are considered to be important for ligand binding and are expressed by several different cell types [29]. The protein produced by the gene forms a heterocomplex with the product of TNFRSF1A, leading to recruitment of two antiapoptotic proteins c-IAP1 and c-IAP2, both of which possess E3 ubiquitin ligase activity. c-IAP1 has been suggested to potentiate TNF-a induced apoptosis through the ubiquitination and degradation of TNF-receptor-associated factor 2, which produces antiapoptotic signals. We have previously shown that TNF-alpha polymorphisms may contribute significantly to the risk of certain IBD phenotypes in the New Zealand population [9]. The present data augment the previous conclusion, that variant alleles associated with this pathway are important for IBD risk in this population.
###end p 29
###begin p 30
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">30</xref>
###xml 331 333 331 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 375 377 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 554 556 554 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 558 560 558 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 562 564 562 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">31</xref>
###xml 746 748 746 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31b">28</xref>
###xml 750 752 750 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31a">32</xref>
###xml 597 605 <span type="species:ncbi:9606">patients</span>
###xml 736 744 <span type="species:ncbi:9606">patients</span>
There are limited data on the functionality of the various SNPs in this gene. However, the 676 T > G polymorphism replaces a methionine by an arginine, and is functional, as the cytotoxic activity is increased [30]. The variant polymorphism has been previously associated with susceptibility to familial rheumatoid arthritis (RA) [20] and systemic lupus erythematosus (SLE) [21]. However, association studies have suggested that the other SNPs considered in the present study might be in linkage with a functional SNP, even if not themselves functional [22, 23, 31]. Perhaps even more relevant to patients with IBD is that associations have recently been demonstrated between a two allele haplotypes and responses to IFB in Japanese CD patients [28, 32].
###end p 30
###begin p 31
###xml 17 19 17 19 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">31</xref>
###xml 311 313 311 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 522 523 522 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 415 423 <span type="species:ncbi:9606">patients</span>
Kawasaki et al. [31] reported no association between the variant SNP at position 676 and the risk of either form of IBD in their Japanese database. These data are consistent with our own findings in the present study. However, these data do not agree with other observations in a European Caucasian population [23] which associated TNFRSF1B with clinical CD phenotypes. They studied a well-phenotyped cohort of 205 patients with CD and 106 controls to associate the variant SNP at this position with increased risk of CD (P = .034), but decreased risk with UC or with the need for surgery. We suggest that the previous European consortium data had insufficient power to conclusively decide a negative result.
###end p 31
###begin p 32
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 337 339 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 620 622 620 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 210 218 <span type="species:ncbi:9606">patients</span>
###xml 232 240 <span type="species:ncbi:9606">patients</span>
It is of some interest that we have associated differences in the risk of certain IBD phenotypes with variant alleles in the other two SNPs considered (1663A > G, or 1690T > C). A Japanese study considered 124 patients with CD, 106 patients with UC, and 111 unrelated healthy controls [22] for these same two SNPs, while Waschke et al. [23] studied the first but not the second in their European Caucasian group. Neither of these previous reports demonstrated a statistically significant difference in carrying either of the variant alleles. We note, however, that in the Japanese population but not in European groups [23], C appears to be the major allele at position 1493.
###end p 32
###begin p 33
###xml 24 26 24 26 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 241 249 <span type="species:ncbi:9606">patients</span>
###xml 314 322 <span type="species:ncbi:9606">patients</span>
Although Sashio et al. [22] reported only minor effects on IBD risk associated with carrying any single variant allele, they found a significant difference (odds ratio of 2.13) in carrier frequency for haplotype AT (1466A, 1493T) between CD patients and the controls. These differences were most significant in CD patients with either internal or external fistula, and/or who responded poorly to nutritional, medical, or surgical therapy. Similar haplotype effects are recorded in the present study. However, we are currently unable to find a convincing explanation of the converse data for UC.
###end p 33
###begin p 34
Although the region containing this gene has not emerged from recent whole genome association studies as a lead candidate in CD (WTCCC, 2007; Barrett et al. 2008) it is of interest that two of the genes consistently appearing important are closely related to the present gene. The protein product of TNFAIP3 (TNF-alpha- induced protein 3) inhibits TNF-alpha-induced NFkB-dependent gene expression by interfering with transactivation signals. Markers with lower levels of significance in these studies include one within TNFSF15 (tumour necrosis factor superfamily, member 15). Taken together, the present data add support to an important role for TNF-alpha and related molecules in CD susceptibility and progression.
###end p 34
###begin title 35
Acknowledgments
###end title 35
###begin p 36
###xml 33 45 <span type="species:ncbi:9606">participants</span>
The authors thank the Canterbury participants in our study. Other funding sources for the case and control DNA collection are the Canterbury Medical Research Foundation, Canterbury Liver and Digestive Diseases Trust, and Christchurch Gastroenterology Research Trust. Nutrigenomics New Zealand is a collaboration between AgResearch Ltd., Crop & Food Research, HortResearch and The University of Auckland. The authors declare no conflicts of interest.
###end p 36
###begin article-title 37
Genes, diet and inflammatory bowel disease
###end article-title 37
###begin article-title 38
Incidence of inflammatory bowel disease is rising and abdominal tuberculosis is falling in Bangladeshis in East London, United Kingdom
###end article-title 38
###begin article-title 39
Genetics of Crohn disease, an archetypal inflammatory barrier disease
###end article-title 39
###begin article-title 40
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
###end article-title 40
###begin article-title 41
High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiologic study
###end article-title 41
###begin article-title 42
Association of DLG5 variants with inflammatory bowel disease in the New Zealand Caucasian population and meta-analysis of the DLG5 R30Q variant
###end article-title 42
###begin article-title 43
Has toll-like receptor 4 been prematurely dismissed as an inflammatory bowel disease gene? Association study combined with meta-analysis shows strong evidence for association
###end article-title 43
###begin article-title 44
###xml 35 40 <span type="species:ncbi:9606">human</span>
Single nucleotide polymorphisms in human Paneth cell defensin A5 may confer susceptibility to inflammatory bowel disease in a New Zealand Caucasian population
###end article-title 44
###begin article-title 45
Single nucleotide polymorphism in the tumor necrosis factor-alpha gene affects inflammatory bowel diseases risk
###end article-title 45
###begin article-title 46
IL23R R381Q and ATG16L1 T300A are strongly associated with Crohn's disease in a study of New Zealand Caucasians with inflammatory bowel disease
###end article-title 46
###begin article-title 47
Confirmation of association of IRGM and NCF4 with ileal Crohn's disease in a population-based cohort
###end article-title 47
###begin article-title 48
Effect of inflammatory bowel disease classification changes on NOD2 genotype-phenotype associations in a population-based cohort
###end article-title 48
###begin article-title 49
###xml 40 45 40 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 121 126 117 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 191 199 <span type="species:ncbi:9606">patients</span>
Analysis of linkage between lymphotoxin alpha haplotype and polymorphisms in 5'-flanking region of tumor necrosis factor alpha gene associated with efficacy of infliximab for Crohn's disease patients
###end article-title 49
###begin article-title 50
###xml 46 51 <span type="species:ncbi:9606">human</span>
Physical mapping and genomic structure of the human TNFR2 gene
###end article-title 50
###begin article-title 51
Signalling pathways of the TNF superfamily: a double-edged sword
###end article-title 51
###begin article-title 52
###xml 28 33 <span type="species:ncbi:9606">human</span>
Chromosomal location of the human tumor necrosis factor receptor genes
###end article-title 52
###begin article-title 53
The gene for the type II (p75) tumor necrosis factor receptor (TNF-RII) is localized on band 1p36.2-p36.3
###end article-title 53
###begin article-title 54
A domain in TNF receptors that mediates ligand-independent receptor assembty and signaling
###end article-title 54
###begin article-title 55
###xml 144 148 144 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IBD1</italic>
Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1
###end article-title 55
###begin article-title 56
Association between tumor necrosis factor receptor II and familial, but not sporadic, rheumatoid arthritis: evidence for genetic heterogeneity
###end article-title 56
###begin article-title 57
Association of tumor necrosis factor receptor 2 (TNFR2) polymorphism with susceptibility to systemic lupus erythematosus
###end article-title 57
###begin article-title 58
Polymorphisms of the TNF gene and the TNF receptor superfamily member 1B gene are associated with susceptibility to ulcerative colitis and Crohn's disease, respectively
###end article-title 58
###begin article-title 59
Tumor necrosis factor receptor gene polymorphisms in Crohn's disease: association with clinical phenotypes
###end article-title 59
###begin article-title 60
Association between rheumatoid arthritis and polymorphism of tumor necrosis factor receptor II, but not tumor necrosis factor receptor I, in Caucasians
###end article-title 60
###begin article-title 61
Perianal disease predicts changes in Crohn's disease phenotype-results of a population-based study of inflammatory bowel disease phenotype
###end article-title 61
###begin article-title 62
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology
###end article-title 62
###begin article-title 63
The significance of haemochromatosis gene mutations in the general population: implications for screening
###end article-title 63
###begin article-title 64
R: a language for data analysis and graphics
###end article-title 64
###begin article-title 65
###xml 51 56 <span type="species:ncbi:9606">human</span>
Molecular cloning and expression of a receptor for human tumor necrosis factor
###end article-title 65
###begin article-title 66
Association of tumor necrosis factor receptor type II polymorphism 196R with systemic lupus erythematosus in the Japanese molecular and functional analysis
###end article-title 66
###begin article-title 67
###xml 44 49 44 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
Independent contribution of HLA-DRB1 and TNFalpha promoter polymorphisms to the susceptibility to Crohn's disease
###end article-title 67
###begin article-title 68
###xml 25 78 25 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">tumour necrosis factor receptor superfamily 1A and 1B</italic>
###xml 122 130 <span type="species:ncbi:9606">patients</span>
Genetic polymorphisms of tumour necrosis factor receptor superfamily 1A and 1B affect responses to infliximab in Japanese patients with Crohn's disease
###end article-title 68
###begin p 69
TNFRSF1B polymorphisms tested in the Canterbury population.
###end p 69
###begin p 70
###xml 70 78 <span type="species:ncbi:9606">patients</span>
Summary of clinical and demographic data for the set of Caucasian IBD patients.
###end p 70
###begin p 71
Primer and probe sequences for custom-made TaqMan SNP genotyping assay for TNFRSF1B.
###end p 71
###begin p 72
###xml 69 77 <span type="species:ncbi:9606">patients</span>
 Genotype and allele counts for TNFRSF1B variants in New Zealand IBD patients and in New Zealand Caucasians.
###end p 72
###begin p 73
###xml 120 128 <span type="species:ncbi:9606">patients</span>
Allelic odds ratios and 95% confidence intervals for comparison of TNFRSF1B variants with IBD status in New Zealand IBD patients and Caucasians.
###end p 73
###begin p 74
###xml 84 92 <span type="species:ncbi:9606">patients</span>
Haplotype analysis of three-SNP TNFRSF1B haplotype in IBD status in New Zealand IBD patients and Caucasians.
###end p 74

